GRACEcast
Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Education (GRACE) is committed to providing the knowledge that will help enable the general public to be informed participants in their own care. Visit cancerGRACE.org for more info.

Thoracic oncologist Dr. Ben Levy highlights what he believes was the biggest news for lung cancer patients in 2014 as well as his take on exciting clinical trials taking place in lung cancer in 2015.


Immunotherapy Forum Video #25: In Part 2 of 2 videos, Dr. Matthew Hellmann discusses currently enrolling clinical trials for lung cancer patients that study combination therapies (meaning an immunotherapy drug plus another drug is given).


Immunotherapy Forum Video #24: In Part 1 of 2 videos, Dr. Matthew Hellmann provides an overview of clinical trials currently available to early and late stage lung cancer patients that study single agent immunotherapies (i.e. only one treatment is given).


Immunotherapy Forum Video #23: Dr. Jared Weiss highlights what doctors know about immunotherapy treatments for lung cancer. His words: "The pace of progress that I expect over the next 3 to 5 years will shock even the most optimistic..."


Immunotherapy Forum Video #22: Drs. Lauren Harshman and Sumanta (Monty) Pal answer questions from the audience following their presentations on immunotherapy for kidney cancer. Moderated by Dr. Marianne Davies.


Immunotherapy Forum Video #21: Dr. Sumanta (Monty) Pal reviews the past, present, and future of immunotherapy for kidney cancer and expresses concern about early study results of newer treatments. 


Immunotherapy Forum Video #20: Dr. Lauren Harshman talks about clinical trials studying the CTLA-4 pathway, as well as vaccines. 


Immunotherapy Forum Video #19: Dr. Lauren Harshman discusses treating kidney cancer with immunotherapy. In this video, she focuses on clinical trials studying PD-1 and PDL-1 agents.